Teva Pharmaceutical Industries Limited

Tel Aviv Stock Exchange:TEVA.TA

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🔬 Clinical Trials

💊 Drugstores & Retail Pharmacies

Location

Israel

Market Cap

USD 19.83 B

Share Price

USD 17.30

Avg Daily Volume

1,949,777

Change (1 day)

1.37%

Change (1 year)

2.20%

Change (YTD)

-22.51%

Teva Pharmaceutical Industries Limited Share Price Year-To-Date (YTD) return on June 19, 2025: -22.51%

Teva Pharmaceutical Industries Limited Share Price Year-To-Date (YTD) return is -22.51% on June 19, 2025. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance. Year-to-Date (YTD) return is is the percentage change in the price of a stock from the start of the calendar year up to the current date, it shows how much the stock has gained or lost since the beginning of the year.

Teva Pharmaceutical Industries Limited 52-week low Share Price is USD 23.02 on June 19, 2025, which is 33.09% above the current Share Price.
Teva Pharmaceutical Industries Limited 52-week low Share Price is USD 13.12 on June 19, 2025, which is -24.15% below the current Share Price.
Teva Pharmaceutical Industries Limited average Share Price for the last 52 weeks is USD 17.59.

Daily

From:

To:

Zoom:

Key data

Date	Share Price Year-To-Date (YTD) return	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)	Price to Sales Ratio (P/S)

Tel Aviv Stock Exchange: TEVA.TA

Teva Pharmaceutical Industries Limited

CEO	Mr. Richard D. Francis
IPO Date	Aug. 12, 2002
Location	Israel
Headquarters	124 Dvora Hanevi’a Street
Employees	37,000
Sector	🏥 Health Care
Industries Pharmaceuticals 🔬 Clinical Trials 💊 Drugstores & Retail Pharmacies

Description

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.